Arrowhead Press Release Archive
December 3, 2007
Arrowhead Names Dr. Chris Anzalone as Chief Executive Officer; Plans to Acquire Nanotechnology Company
November 29, 2007
Arrowhead subsidiary, Unidym, selected as a 2008 technology pioneer by the World Economic Forum
November 27, 2007
Unidym's Dr. Paul Drzaic Speaking at Materials Research Society Fall Meeting
November 2, 2007
Arrowhead and Subsidiary, Unidym, to Present at Global Crown Capital Nanotechnology Investment Conference
November 1, 2007
Arrowhead and Subsidiary, Unidym, to Present at the AeA Classic Finacial Conference
October 31, 2007
Arrowhead Subs, Calando and Insert, Appoint Larry Stambaugh as CEO and President
October 25, 2007
Arrowhead Research Corporation Injects Capital Into Subsidiary Tego Biosciences Corporation
October 16, 2007
Unidym CEO to Speak at Lux Executive Summit
October 9, 2007
Insert Therapeutics’ Lead Anti-Cancer Compound is Highlighted in Public Television Documentary
October 5, 2007
Arrowhead Subsidiary, Aonex, Demonstrates High Quality Gan Growth on Its Proprietary A-Gan™ Substrates which Target the Gan Laser Diode and Led Device Markets
September 25, 2007
New Research Published on Impact of Targeting on Biodistribution and Efficacy of siRNA Using Calando Pharmaceuticals siRNA Delivery Technology
September 24, 2007
Arrowhead Subsidiary, Insert Therapeutics, Awarded Patent for Cyclosert™ Camptothecin, the Company's Lead Oncology Candidate
September 12, 2007
U.S. Patent and Trademark Office Issues Fundamental Patent for Carbon Nanotube-Based Transparent Electrodes
August 23, 2007
Unidym Appoints Leading Display and Flexible Electronics Industry Expert as Chief Technology Officer
August 14, 2007
Arrowhead Subsidiary, Unidym, Inc., Appoints Semiconductor Industry Executive as Vice President of Business Development & Marketing
August 3, 2007
Arrowhead Subsidiary Licenses Technology to Incorporate Carbon Nanotubes into Miniaturized Medical Devices for the Treatment of Cardiovascular Disease
August 2, 2007
Arrowhead Subsidiary Unidym Signs Joint Development Agreement for Printable Conductors with Interphases' Thin-Film Solar Cells
July 30, 2007
Arrowhead Subsidiary Signs Agreement to Integrate Its Products into Major Display Manufacturer's Flat Panel Displays
July 12, 2007
Arrowhead Subsidiary Unidym Signs Strategic Alliance with Battelle
July 2, 2007
Unidym Announces Establishment of Technical Advisory Board
June 28, 2007
Arrowhead Upgrades Listing to NASDAQ Global Market
June 25, 2007
Arrowhead's New Nanobioscience Subsidiary Plans Preclinical Studies and Collaboration with NCI
June 18, 2007
Arrowhead Subsidiary, Unidym, Inc., Appoints Semiconductor Industry Executive as Chief Executive Officer
June 13, 2007
Arrowhead Scheduled to be Listed on Russell 3000 Index
June 1, 2007
Arrowhead Subsidiary, Insert, Publishes Interim Phase I Data from Human Clinical Trials for New Cancer Drug
May 18, 2007
Arrowhead Announces $16.5 Million Investment by Institutional Investors
May 17, 2007
Arrowhead Subsidiary, Insert Therapeutics, to Present at Institutional Investor Conference
May 11, 2007
Arrowhead Subsidiary, Calando Pharmaceuticals, Plans First to Humans Clinical Trial with Targeted, Nano-Delivered
May 8, 2007
Arrowhead Announces Issuance of Patent on Subsidiary's Key Technology
May 4, 2007
Arrowhead And Subsidiary, Unidym, Selected to Present at ThinkEquity Private Company and Venture Capital Summit
April 24, 2007
Arrowhead Subsidiary Unidym Signs Joint Development Agreement for Touch Panels in Video Game Machines
April 23, 2007
Arrowhead Subsidiary Unidym, and Carbon Nanotechnologies, Inc. Close Merger
April 17, 2007
Arrowhead to Present at Nanobusiness Alliance Conference
April 16, 2007
Arrowhead Subsidiaries Insert & Calando Present Data on Cyclosert™ Drug Delivery System at AACR Meeting
April 12, 2007
Mark Davis to Moderate "Novel Approaches to Drug Delivery in Cancer" Session at the AACR Meeting
April 3, 2007
Arrowhead Subsidiary Calando Pharmaceuticals Publishes Study Showing Anti-Cancer Effect with Lead RNAi Candidate
March 26, 2007
Arrowhead to form New Nanomedicine Subsidiary and Acquire Nanotherapeutics Company, C Sixty, Inc.
March 22, 2007
Arrowhead Subsidiary, Unidym, to Merge with Carbon Nanotechnologies, Inc.
March 20, 2007
Arrowhead Subsidiary, Calando Pharmaceuticals Publishes Study on Targeted, Systemic Delivery of siRNA
March 1, 2007
Insert Therapeutics Signs New Partnership with R&D Biopharmaceuticals
February 26, 2007
Arrowhead Subsidiary Collaborates with Kyma Technologies to Reduce the Cost of Blue Lasers and Blue Leds
February 12, 2007
Arrowhead Licenses Dip Pen Nanolithography Technology to Nanoink
February 8, 2007
Arrowhead Subsidiary, Unidym, Establishes Headquarters in Silicon Valley
January 25, 2007
Arrowhead to Fund Stem Cell Research at Caltech
January 17, 2007
Arrowhead Subsidiary, Insert Therapeutics, Signs Collaboration and Option Agreement for Potent Anti-Cancer Compound, Tubulysin
January 9, 2007
Arrowhead Subsidiary, Unidym, Signs a Collaboration Agreement with IMRE to Develop Organic Light Emitting Diodes Incorporating Unidym's Transparent Electrodes
November 29, 2006
Arrowhead Subsidiary, Aonex Technologies, Inc., Demonstrates GaN Growth on Proprietary Substrates that Nearly Eliminate Thermal-Induced Bowing; Announces Low Cost Replacement for Bulk GaN Substrates for Use in the Projected $10 Billion GaN Device Market
October 26, 2006
Arrowhead Subsidiary, Insert Therapeutics, Inc., Raises $10 Million in Private Equity Financing
October 24, 2006
Arrowhead Selected to Present at Global Crown Capital's Nanotechnology Investment Conference
October 20, 2006
Calando Pharmaceuticals' Lead siRNA Anti-Cancer Therapeutic Candidate Shown to be Well Tolerated in Non-Human Primate Safety Study
October 12, 2006
Arrowhead Subsidiary, Insert Therapeutics, to Hire Pharmaceutical Executive as Chief Executive Officer
October 11, 2006
Arrowhead Subsidiary, Calando Pharmaceuticals, to Present Preclinical Results of Non-Human Primate Studies at Oligonucleotide Therapeutic Society Annual Meeting
September 12, 2006
Arrowhead Subsidiary, Insert Therapeutics, Featured in Pasadena Star-News
September 7, 2006
Arrowhead Selected to Present at ThinkEquity Partners Growth Conference
September 6, 2006
Calando Pharmaceuticals Announces Initial RNAi Product, Goals for 2007
August 31, 2006
Arrowhead Subsidiaries Selected to Present at Credit Suisse Nanotechnology Conference
August 24, 2006
Arrowhead Names Paul Mcdonnel as Vice President, Finance & Accounting
August 18, 2006
Arrowhead Raises Additional Capital from Institutional Shareholders; Increases Ownership in RNAi Subsidiary
August 3, 2006
Arrowhead Research Partners with Rinzler Lab at University of Florida to Make Flexible Thin Film Transistors Aimed at the Estimated $20 Billion Flexible Electronics Market
July 26, 2006
Calando Pharmaceuticals Selects Agilent Technologies for siRNA Production
July 25, 2006
Arrowhead Research Subsidiary, Nanopolaris, Changes Name to Unidym
July 19, 2006
Arrowhead Research Subsidiary, Insert Therapeutics, Treats First Patient with Nano-Engineered Anti-Cancer Therapeutic
July 7, 2006
Arrowhead Research Chairman & Ceo to Speak At NanoEquity 2006
June 21, 2006
Arrowhead Research Corporation Scheduled to be Listed on Russell Microcap Index
June 14, 2006
Arrowhead Research's NanoPolaris Acquires Assets in Unidym, a Carbon Nanostructure Electrics Company; Arrowhead Commits $7 Million to Scale up Production and Device Integration
May 16, 2006
Arrowhead Research VP of Intellectual Property to Speak at NanoBusiness 2006
May 5, 2006
Arrowhead Research Subsidiary Founding Scientist, Dr. Mark E. Davis, Elected to the National Academy of Sciences
April 12, 2006
Arrowhead Announces the Issuance of Patent Covering a New Approach to Targeted Therapeutics
March 14, 2006
Arrowhead Research Subsidiary, Insert Therapeutics, Receives FDA Approval for IT-101 Phase 1 Clinical Trials for Patented Nanotechnology-Based Therapeutic Set to Begin
February 9, 2006
Insert Therapeutics Files Investigational New Drug Application for Lead Anti-Cancer Compound IT-101
February 3, 2006
Arrowhead Subsidiary Calando to Jointly Develop RNAi Therapeutics to Fight Childhood Cancer with the National Cancer Institute
January 25, 2006
Arrowhead Closes $19.6 Million Investment by York Capital Management and Knott Partners
January 13, 2006
Arrowhead Announces $19.6 Million Investment by York Capital Management and Knott Partners
January 10, 2006
Arrowhead Added to Powershares Lux Nanotech Exchange Traded Fund
December 8, 2005
Arrowhead Assembles a Carbon Nanotube Patent Portfolio Through Exclusive Licenses with Leading Universities
November 10, 2005
Nanotech Company Arrowhead Names Dr. Leon Ekchian President; Experienced Leader Has Background in Science and Commercialization
November 4, 2005
Arrowhead and Duke University Begin Work on Nanotubes to Replace Copper, the Semiconductor Industry's Weakest Link
October 11, 2005
Arrowhead Accelerates Capital Contribution to Insert Therapeutics as Nanotech Cancer Drug Heads Toward Clinical Trials
October 4, 2005
Newly Published Results Demonstrate Potential of Arrowhead Subsidiary's Technology as a New Tool in Fight Against Cancer
September 14, 2005
Arrowhead Appoints Virginia Dadey as Vice President, Investor Relations
August 25, 2005
Lovy to Join Arrowhead Team as Communications Director
August 16, 2005
Esteemed Scientist Joins Arrowhead Scientific Advisory Board
August 11, 2005
Arrowhead Announces SBIR Award to Subsidiary for Improved Solar Cells
June 21, 2005
Arrowhead Announces Licensing by Subsidiary of RNAi Delivery Technology to Benitec
June 16, 2005
Arrowhead Completes Warrant Redemption; Receives over $20 Million in Net Proceeds
June 14, 2005
Exercise Deadline of Arrowhead Warrants is at 4:00 P.M. PT Today
June 9, 2005
Arrowhead's Warrants Delisted from Nasdaq after the Close of Business on Wednesday, June 8, 2005
June 6, 2005
Arrowhead Announces License of New Nanotech Stem Cell Device from Stanford University
June 2, 2005
Exercise Deadline for Arrowhead's Warrant Redemption is Tuesday, June 14, 2005 – Redemption Scheduled to Close Wednesday, June 15, 2005
May 19, 2005
Arrowhead Research Corporation Acquires Early Nanosensor Patent Portfolio
May 4, 2005
Arrowhead Announces Redemption of Stock Purchase Warrants
April 26, 2005
Arrowhead Plans to Redeem Stock Purchase Warrants
April 21, 2005
Arrowhead Subsidiary Reports Non-Viral, Systemic Inhibition of Tumor Growth in Animals with siRNA
April 20, 2005
Arrowhead Subsidiary Successful in Small Animal Studies for Anti-Cancer Compound IT-101
April 13, 2005
Arrowhead Announces Patent Grant on Spintronic Technology for Use in Next-Generation Semiconductor Devices
March 30, 2005
Arrowhead Research to Present At The Stephens, Inc. Nanotechnology Investor Conference
March 29, 2005
Dr. Richmond Wolf to Chair Arrowhead Research Corporation's Advisory Board
March 10, 2005
Arrowhead Announces Expansion of Nanotech Intellectual Property Portfolio
February 22, 2005
Arrowhead Research Launches New Subsidiary to Focus on Delivery and Therapeutic Use of RNA Interference